President Trump’s December 2025 executive order directed expedited rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. In April 2026 the Department of Justice and DEA issued an order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching a streamlined administrative hearing process for broader rescheduling. That hearing is scheduled to begin June 29, 2026, with firm procedural deadlines intended to accelerate a final rulemaking decision. These steps follow the 2023 HHS recommendation and 2024 proposed rule, providing the clearest near-term path for full federal rescheduling and directly shaping trader assessments of resolution timing.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert$762,420 Vol.
30. Juni
2%
31. Dezember
26%
$762,420 Vol.
30. Juni
2%
31. Dezember
26%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Markt eröffnet: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...President Trump’s December 2025 executive order directed expedited rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. In April 2026 the Department of Justice and DEA issued an order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching a streamlined administrative hearing process for broader rescheduling. That hearing is scheduled to begin June 29, 2026, with firm procedural deadlines intended to accelerate a final rulemaking decision. These steps follow the 2023 HHS recommendation and 2024 proposed rule, providing the clearest near-term path for full federal rescheduling and directly shaping trader assessments of resolution timing.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen